Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease
HiroshimaJMedSci_60_57.pdf 408 KB
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
Hiroshima Journal of Medical Sciences
Hiroshima University Medical Press
(c) Hiroshima University Medical Press.
過去1年のアクセス数 : ? 件
過去1年の本文閲覧数 : ? 件
今月のアクセス数 : ? 件
今月の本文閲覧数 : ? 件